What Happened?
A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as investors reacted to escalating uncertainty tied to the U.S.-Iran conflict and policy deadlines set by the Trump administration.
Markets dislike unpredictability, and these fears were amplified, raising concerns of prolonged conflict and rising oil prices. This negative outlook reflected in consumer confidence, with the University of Michigan's sentiment index sliding to a three-month low.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.
Among others, the following stocks were impacted:
- Medical Devices & Supplies - Specialty company Enovis (NYSE: ENOV) fell 4.6%. Is now the time to buy Enovis? Access our full analysis report here, it’s free.
- Medical Devices & Supplies - Diversified company Neogen (NASDAQ: NEOG) fell 3.4%. Is now the time to buy Neogen? Access our full analysis report here, it’s free.
- Health Insurance Providers company Humana (NYSE: HUM) fell 4.3%. Is now the time to buy Humana? Access our full analysis report here, it’s free.
- Outpatient & Specialty Care company LifeStance Health Group (NASDAQ: LFST) fell 4.4%. Is now the time to buy LifeStance Health Group? Access our full analysis report here, it’s free.
- Healthcare Technology for Patients company Hims & Hers Health (NYSE: HIMS) fell 6.4%. Is now the time to buy Hims & Hers Health? Access our full analysis report here, it’s free.
Zooming In On Hims & Hers Health (HIMS)
Hims & Hers Health’s shares are extremely volatile and have had 76 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 18 days ago when the stock gained 41.7% on the news that the company announced a collaboration with drugmaker Novo Nordisk to sell its popular GLP-1 weight-loss drugs, which also resolved a recent legal dispute.
The deal marked a surprising turn, as Novo Nordisk had been in a legal battle with Hims & Hers over the sale of compounded versions of its blockbuster drugs. As part of the new partnership, Hims & Hers gained the ability to offer FDA-approved medications like Ozempic and Wegovy directly on its platform. In return, the company planned to limit its offering of compounded semaglutide and stop advertising those products. Following the announcement, Novo Nordisk dismissed its lawsuit against the company, signaling an end to their feud. The agreement was viewed as a strategic shift for Hims & Hers, moving it from a market disruptor to a more established healthcare provider.
Hims & Hers Health is down 41.8% since the beginning of the year, and at $19.46 per share, it is trading 70.6% below its 52-week high of $66.18 from July 2025. Despite the year-to-date decline, investors who bought $1,000 worth of Hims & Hers Health’s shares 5 years ago would now be looking at an investment worth $1,521.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
